文献速递癫痫脑血管病

老年癫痫患者使用拉莫三嗪与室性心律失常及心脏骤停风险

Risk of Ventricular Arrhythmia and Sudden Cardiac Arrest Among Older Patients Using Lamotrigine for Epilepsy.
PubMed 文献 · Neurology · 2025-06-11

本研究为回顾性队列研究,纳入2007-2019年65岁及以上癫痫患者,比较拉莫三嗪与左乙拉西坦新使用者的室性心律失常/心脏骤停(VA/SCA)风险。结果显示拉莫三嗪组VA/SCA发生率未显著升高(HR 0.84,95%CI 0.67-1.06),在基线心律失常或使用抗心律失常药亚组中风险显著降低。

要点

  • 老年癫痫患者中,拉莫三嗪与左乙拉西坦相比未增加VA/SCA风险。
  • 基线有心律失常者使用拉莫三嗪风险显著降低(HR 0.51)。
  • 研究结果不支持拉莫三嗪心脏风险及安全标签修改。

核心结论

  • 在老年癫痫患者中,拉莫三嗪与左乙拉西坦相比未增加室性心律失常/心脏骤停风险。

研究设计与样本

  • 回顾性队列研究,纳入2007-2019年65岁及以上癫痫患者,拉莫三嗪新用户11,786例,左乙拉西坦新用户147,130例,平均年龄77.6岁,女性占60.5%。

主要发现

  • 拉莫三嗪组VA/SCA发生率为7.0/1000人年,左乙拉西坦组为8.2/1000人年,HR 0.84(95%CI 0.67-1.06)。
  • 基线有心律失常亚组中,拉莫三嗪组VA/SCA风险显著降低(HR 0.51,95%CI 0.32-0.80)。
  • 使用抗心律失常药亚组中,拉莫三嗪组风险也显著降低(HR 0.67,95%CI 0.50-0.91)。

临床怎么用

  • 对于老年癫痫患者,尤其合并心脏病者,拉莫三嗪未显示增加VA/SCA风险,可依据病情选用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Lamotrigine, an antiseizure medication, blocks the activation of voltage-gated sodium channels and reduces the excitability of cardiomyocytes in vitro. Based on concerns for QT prolongation and case reports of arrhythmias among lamotrigine users, the US Food and Drug Administration placed a safety warning on lamotrigine's label in 2020. However, limited evidence exists on the cardiac risk of lamotrigine in patients with epilepsy. This study assessed whether lamotrigine users with epilepsy had an increased risk of ventricular arrhythmia and sudden cardiac arrest (VA/SCA) compared with users of levetiracetam. METHODS: This was a retrospective cohort study among Medicare-insured individuals aged 65 years or older with epilepsy (2007-2019). We identified new users of lamotrigine and levetiracetam without inpatient or emergency VA/SCA diagnosis in the 12-month continuous enrollment baseline period before initiation of treatment. Using inverse probability of treatment weighting derived from propensity scores based on baseline covariates, we compared adjusted incidence rates of inpatient or emergency VA/SCA events in lamotrigine vs levetiracetam users and estimated adjusted hazard ratios (HRs) with 95% CIs using Cox proportional hazard regression. RESULTS: The study cohort (mean age 77.6 years and 60.5% female) consisted of 11,786 new lamotrigine users and 147,130 new levetiracetam users. At baseline, lamotrigine users were younger and less likely to have cardiovascular and noncardiovascular comorbidities than the levetiracetam users. The incidence and HR of VA/SCA were not statistically higher among lamotrigine users (7.0 vs 8.2 per 1,000 person-years for the lamotrigine and levetiracetam users, respectively; HR 0.84, 95% CI 0.67-1.06). Secondary analyses stratified by baseline cardiac abnormalities showed significantly reduced risk among lamotrigine users in subgroups with baseline arrhythmia (HR 0.51, 95% CI 0.32-0.80) or use of antiarrhythmic drugs (HR 0.67, 95% CI 0.50-0.91). DISCUSSION: In older adults with epilepsy, lamotrigine was not associated with an increased risk of VA/SCA compared with levetiracetam, including among those with underlying heart disease. Our findings do not support the reported cardiac risks associated with lamotrigine or the recent changes to its safety label.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ho GYF, Horton DB, Patel PJ, et al. Risk of Ventricular Arrhythmia and Sudden Cardiac Arrest Among Older Patients Using Lamotrigine for Epilepsy. Neurology. 2025. PMID: 40499084. doi:10.1212/WNL.0000000000213643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。